Altrova Health Reports Third Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
Altrova Health (OTCQB: ATVHF) reported Q3 Fiscal 2026 results for the nine months ended June 30, 2026, with revenue rising to $112,000 from $15,551 a year earlier, driven by commercialization of its NIRLAB distribution channels and broader recurring sales activity.
Gross profit increased to $62,488, while gross margin declined to 55.8% from 62.4%, reflecting a shift from early-stage transactions to more diversified commercial sales. Net and comprehensive loss widened to $2,351,996 from $1,098,177, with over 60% of the increase attributed to a non-cash $330,640 write-off from terminating an exclusive license and a $463,785 rise in non-cash share-based compensation.
According to Altrova Health, the company achieved its first meaningful product revenue, expanded its distribution network with NIRLAB device sales and Indigenous and First Nations partnerships, completed a rebrand and cross-border uplisting (CSE: ROVA, OTCQB: ATVHF), and reduced general and administrative, investor relations and professional fees.
Positive
- Revenue growth to $112,000 from $15,551 over nine months
- Gross profit rose to $62,488 from $9,702 over nine months
- Operating cost discipline with lower G&A, investor relations and professional fees year-over-year
- Non-cash items drove over 60% of net loss increase, limiting cash impact
- Rebrand and uplisting completed on CSE (ROVA) and OTCQB (ATVHF)
Negative
- Net and comprehensive loss increased to $2,351,996 from $1,098,177
- Gross margin declined to 55.8% from 62.4% over nine months
- One-time non-cash charge of $330,640 from license termination
- Higher management and consulting fees to support expanded platform
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today announced its financial results for the three and nine-month periods ended June 30, 2026 ("Q3 Fiscal 2026"). The Company's condensed interim consolidated financial statements and related management's discussion and analysis for the period (collectively, the "Interim Filings") have been filed under the Company's profile on SEDAR+ at www.sedarplus.ca. All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated.
Q3 Fiscal 2026 Highlights:
First commercial revenue: nine-month revenue of
$112,000 , up from$15,551 in the prior comparative period, as distribution and commercialization initiatives put in place over the past year began converting into recurring commercial activity for the first time in the Company's history.Expanding distribution network: continued NIRLAB SA ("NIRLAB") device sales, expanded partnerships with Indigenous and First Nations communities, and a planned relaunch of the Drug Lab 118 Ltd. rapid detection strip portfolio.
Completed rebrand and cross-border uplisting: shares now trade as Altrova Health Inc. on the CSE (ROVA) and OTCQB (ATVHF), aligning the Company's US and Canadian trading identity with its healthcare platform.
Lower discretionary costs: general and administrative, investor relations and professional fees each declined year-over-year even as the Company scaled its commercial operations.
Management Commentary
"This quarter marks an important turning point for Altrova," said Geoff Benic, Chief Executive Officer of Altrova Health. "Generating our first meaningful product revenue tells us that the distribution relationships and commercial partnerships we have built over the past year are starting to convert into real activity. Combined with a refreshed board and leadership team, we believe we are building the foundation to carry that momentum forward."
"This quarter reflects the direction the board wants to see from this management team," said The Hon. Tony Clement, Chairman of the Board of Altrova Health. "The Company is beginning to show real commercial progress, and it's doing so with the financial discipline and leadership strength this stage of growth requires. The board's role now is to keep holding management to that standard."
Financial Summary
Selected results for the nine-month period ended June 30, 2026, compared to the nine-month period ended June 30, 2025:
| Results of Operations | Nine Months Ended June 30, 2026 | Nine Months Ended June 30, 2025 | ||||
| Revenue | $ | 112,000 | $ | 15,551 | ||
| Gross Profit | $ | 62,488 | $ | 9,702 | ||
| Gross Margin | ||||||
| Net loss and comprehensive loss | $ | (2,351,996 | ) | $ | (1,098,177 | ) |
Altrova's third fiscal quarter results reflect a company translating a year of distribution and commercialization work into measurable commercial output for the first time. Revenue grew to
Net loss and comprehensive loss increased to
About Altrova Health Inc.
Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA ("NIRLAB") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line, alongside the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd.
For more information, please visit: www.altrovahealth.com.
On behalf of the Board of Directors of Altrova Health Inc.
"Geoff Benic"
Geoff Benic, CEO
Media & Investor Contact:
Altrova Health Inc.
Email: info@altrovahealth.com
Geoff Benic, Chief Executive Officer
Email: geoff@altrovahealth.com
Phone: +1 647-880-7314
Website: www.altrovahealth.com
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company's expectations for the continued growth of its commercial and distribution network, including NIRLAB device sales and the planned relaunch of the Drug Lab 118 rapid detection strip portfolio; management's and the board's expectations regarding the Company's ability to convert its distribution and commercial relationships into recurring revenue; the Company's ability to build on the operational momentum described in this news release; and the Company's future growth, profitability and business prospects generally.
Forward-looking statements are based on a number of estimates and assumptions that, while considered reasonable by management as of the date of this news release, are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include, among others: the Company's limited operating history and history of losses; uncertainty as to whether the Company will continue to generate revenue or achieve profitability; the Company's ability to continue as a going concern, as described in the Interim Filings; the Company's dependence on additional equity or debt financing to fund its operations, which may not be available on acceptable terms or at all; risks associated with the commercialization of new products and technologies, including market acceptance and competition; the Company's reliance on third-party distribution, licensing and supply relationships; regulatory risks applicable to the Company's products in the jurisdictions in which it operates; and general economic, market and industry conditions.
Additional risks and uncertainties are described in the Company's continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312309